{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T04:48:39Z","timestamp":1774241319455,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Haematology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/s2352-3026(15)00153-2","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T05:13:22Z","timestamp":1445750002000},"page":"e492-e502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":145,"title":["Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials"],"prefix":"10.1016","volume":"2","author":[{"given":"Maja V","family":"Maraldo","sequence":"first","affiliation":[]},{"given":"Francesco","family":"Giusti","sequence":"additional","affiliation":[]},{"given":"Ivan R","family":"Vogelius","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Lundemann","sequence":"additional","affiliation":[]},{"given":"Marleen A E","family":"van der Kaaij","sequence":"additional","affiliation":[]},{"given":"Safaa","family":"Ramadan","sequence":"additional","affiliation":[]},{"given":"Bart","family":"Meulemans","sequence":"additional","affiliation":[]},{"given":"Michel","family":"Henry-Amar","sequence":"additional","affiliation":[]},{"given":"Berthe M P","family":"Aleman","sequence":"additional","affiliation":[]},{"given":"John","family":"Raemaekers","sequence":"additional","affiliation":[]},{"given":"Paul","family":"Meijnders","sequence":"additional","affiliation":[]},{"given":"Elisabeth C","family":"Moser","sequence":"additional","affiliation":[]},{"given":"Hanneke C","family":"Kluin-Nelemans","sequence":"additional","affiliation":[]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[]},{"given":"Catherine","family":"Fortpied","sequence":"additional","affiliation":[]},{"given":"Lena","family":"Specht","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S2352-3026(15)00153-2_bib1","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/S2352-3026(15)00153-2_bib2","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/jama.1993.03510160067031","article-title":"Factors affecting late mortality from heart disease after treatment of Hodgkin's disease","volume":"270","author":"Hancock","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/S2352-3026(15)00153-2_bib3","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","article-title":"Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy","volume":"290","author":"Hull","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/S2352-3026(15)00153-2_bib4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jnci\/djk029","article-title":"Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study","volume":"99","author":"Swerdlow","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S2352-3026(15)00153-2_bib5","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/S2352-3026(15)00153-2_bib6","doi-asserted-by":"crossref","first-page":"djv018","DOI":"10.1093\/jnci\/djv018","article-title":"Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood","volume":"107","author":"Matasar","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S2352-3026(15)00153-2_bib7","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/S2352-3026(15)00153-2_bib8","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved-field radiotherapy for advanced Hodgkin's lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/S2352-3026(15)00153-2_bib9","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S2352-3026(15)00153-2_bib10","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/S2352-3026(15)00153-2_bib11","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/S2352-3026(15)00153-2_bib12","doi-asserted-by":"crossref","first-page":"djv008","DOI":"10.1093\/jnci\/djv008","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S2352-3026(15)00153-2_bib13","doi-asserted-by":"crossref","first-page":"b4606","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/S2352-3026(15)00153-2_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2141.2011.08713.x","article-title":"Review of the cardiac long-term effects of therapy for Hodgkin lymphoma","volume":"154","author":"Ng","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/S2352-3026(15)00153-2_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/JCO.1988.6.2.239","article-title":"Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors","volume":"6","author":"Carde","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/S2352-3026(15)00153-2_bib16","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.1993.11.11.2258","article-title":"Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group","volume":"11","author":"Carde","year":"1993","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/S2352-3026(15)00153-2_bib17","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.V106.11.814.814","article-title":"Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's Lymphoma (HL): preliminary results of the EORTC-GELA H9-F trial","volume":"106","author":"Eghbali","year":"2005","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/S2352-3026(15)00153-2_bib18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1182\/blood.V106.11.813.813","article-title":"Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin's Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial","volume":"106","author":"Ferme","year":"2005","journal-title":"Blood"},{"key":"10.1016\/S2352-3026(15)00153-2_bib19","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/S2352-3026(15)00153-2_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/JCO.1994.12.2.279","volume":"12","author":"Somers","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/S2352-3026(15)00153-2_bib21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0014-2964(79)90138-5","article-title":"Long-term results of the E.O.R.T.C. randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin's disease","volume":"15","author":"Tubiana","year":"1979","journal-title":"Eur J Cancer"},{"key":"10.1016\/S2352-3026(15)00153-2_bib22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0014-2964(81)90128-6","article-title":"Five-year results of the EORTC randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin's disease","volume":"17","author":"Tubiana","year":"1981","journal-title":"Eur J Cancer"},{"key":"10.1016\/S2352-3026(15)00153-2_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B Methodol"},{"key":"10.1016\/S2352-3026(15)00153-2_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.radonc.2015.01.008","article-title":"A new method to estimate doses to the normal tissues after past extended and involved field radiotherapy for Hodgkin lymphoma","volume":"114","author":"Maraldo","year":"2015","journal-title":"Radiother Oncol"},{"issue":"suppl 3","key":"10.1016\/S2352-3026(15)00153-2_bib25","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation dose-volume effects in the heart","volume":"76","author":"Gagliardi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/S2352-3026(15)00153-2_bib26","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1118\/1.1568978","article-title":"CERR: a computational environment for radiotherapy research","volume":"30","author":"Deasy","year":"2003","journal-title":"Med Phys"},{"key":"10.1016\/S2352-3026(15)00153-2_bib27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","article-title":"Checking the Cox model with cumulative sums of martingale-based residuals","volume":"80","author":"Lin","year":"1993","journal-title":"Biometrika"},{"key":"10.1016\/S2352-3026(15)00153-2_bib28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2010-06-291328","article-title":"Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation","volume":"117","author":"Galper","year":"2011","journal-title":"Blood"},{"key":"10.1016\/S2352-3026(15)00153-2_bib29","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1080\/10428190802140873","article-title":"Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy","volume":"49","author":"Myrehaug","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/S2352-3026(15)00153-2_bib30","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/S2352-3026(15)00153-2_bib31","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jclinepi.2004.04.005","article-title":"Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure","volume":"57","author":"Okura","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/S2352-3026(15)00153-2_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/oxfordjournals.aje.a009653","article-title":"Validation of patient recall of doctor-diagnosed heart attack and stroke: a postal questionnaire and record review comparison","volume":"148","author":"Walker","year":"1998","journal-title":"Am JEpidemiol"}],"container-title":["The Lancet Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352302615001532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352302615001532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:19:58Z","timestamp":1718151598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352302615001532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S2352302615001532"],"URL":"https:\/\/doi.org\/10.1016\/s2352-3026(15)00153-2","relation":{},"ISSN":["2352-3026"],"issn-type":[{"value":"2352-3026","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials","name":"articletitle","label":"Article Title"},{"value":"The Lancet Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S2352-3026(15)00153-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S2352-3026(15)00194-5","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}